ClinicalTrials.gg

Program

chiglitazar

Also written as “Chiglitazar”, “Chiglitazar/Metformin extended-release tablets under fasting conditions” and “Chiglitazar/Metformin extended-release tablets after a high-fat meal”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Chipscreen Biosciences.

Furthest: phase 3, since Apr 22, 20149 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciences90 open or runningphase 3since Apr 22, 2014Apr 22, 2014none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2014First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT02121717 · 535 enrolled · China
  2. Jun 20, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02173457 · 740 enrolled · China
  3. Mar 17, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04807348 · 533 enrolled · China
  4. Dec 3, 2021Phase 2 study in NASHNCT05193916 · 104 enrolled · China
  5. Aug 23, 20222 phase 1 studiesNCT05515458, NCT05515445
  6. Dec 27, 2022Phase 1 study in T2DMNCT05681273 · 48 enrolled · China
  7. Mar 20, 2026No phase study in Diabetes Mellitus, Type 2NCT07519265 · 64 enrolled · China
  8. Mar 20, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07511010 · 28 enrolled · China

TargetBeta

“Peroxisome proliferator-activated receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
lanifibranorinventiva-pharmaphase 36

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07519265Diabetes Mellitus, Type 2 · China–CompletedAug 3, 202664
NCT07511010Diabetes Mellitus, Type 2 · China1CompletedOct 22, 202628
NCT05681273T2DM · China1CompletedMar 21, 202348
NCT05515458Renal Insufficiency · China1CompletedJul 19, 202324
NCT05515445Hepatic Impairment · China1CompletedAug 23, 202324
NCT05193916NASH · China2CompletedJan 2, 2024104
NCT04807348Diabetes Mellitus, Type 2 · China3CompletedFeb 10, 2023533
NCT02173457Diabetes Mellitus, Type 2 · China3CompletedJan 2017740
NCT02121717Diabetes Mellitus, Type 2 · China3CompletedNov 2017535

How it is read

Names in the registry

  • “Chiglitazar”, 5 entries
  • “Chiglitazar/Metformin extended-release tablets under fasting conditions”, 1 entry
  • “Chiglitazar/Metformin extended-release tablets after a high-fat meal”, 1 entry
  • “multiple-dose of Chiglitazar/Metformin extended-release tablets”, 1 entry
  • “Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.